163 related articles for article (PubMed ID: 28186999)
1. Design, sythesis and evaluation of a series of 3- or 4-alkoxy substituted phenoxy derivatives as PPARs agonists.
Zhang J; Wang XJ; Liu X; Huan Y; Yang MM; Shen ZF; Jia WQ; Jing Z; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Mar; 8(13):20766-20783. PubMed ID: 28186999
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
Gani OA; Sylte I
J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.
Yasmin S; Jayaprakash V
Eur J Med Chem; 2017 Jan; 126():879-893. PubMed ID: 27988463
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
7. [4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs).
Sparatore A; Godio C; Perrino E; Romeo S; Staels B; Fruchart JC; Crestani M
Chem Biodivers; 2006 Apr; 3(4):385-95. PubMed ID: 17193275
[TBL] [Abstract][Full Text] [Related]
8. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
9. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.
Ammazzalorso A; Carrieri A; Verginelli F; Bruno I; Carbonara G; D'Angelo A; De Filippis B; Fantacuzzi M; Florio R; Fracchiolla G; Giampietro L; Giancristofaro A; Maccallini C; Cama A; Amoroso R
Eur J Med Chem; 2016 May; 114():191-200. PubMed ID: 26974385
[TBL] [Abstract][Full Text] [Related]
11. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
[TBL] [Abstract][Full Text] [Related]
13. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
16. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
[TBL] [Abstract][Full Text] [Related]
17. The next generation of PPAR drugs: do we have the tools to find them?
Shearer BG; Billin AN
Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
19. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.
Ammazzalorso A; De Filippis B; Giampietro L; Amoroso R
ChemMedChem; 2013 Oct; 8(10):1609-16. PubMed ID: 23939910
[TBL] [Abstract][Full Text] [Related]
20. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
